Medtronic plc owns Micra. It is an internally developed product line within Medtronic's Cardiovascular segment. Medtronic trades on the NYSE under ticker MDT.

No. Micra is a product brand, not a corporate entity. It has never been a standalone company.

When was Micra launched?

Micra was first commercialized under CE Mark in 2015 and received FDA approval in April 2016. The second-generation AV2 and VR2 versions were FDA approved in 2023.

How many patients have a Micra?

Medtronic reports more than 300,000 patients implanted worldwide, with more than 10,000 trained implanting physicians as of 2025.

What is Micra's market position?

Micra is the leading leadless pacemaker globally and the category's original product. Its main competitor is Abbott's Aveir, approved in the United States in 2023.

Micra is manufactured in Medtronic facilities in the United States and Puerto Rico, within the company's cardiac device production network.

Healthcare & Pharmaceuticals

Who Owns Micra?

Micra is Medtronic plc's (NYSE: MDT) family of leadless pacemakers, the smallest pacemakers in the world. Developed internally and first commercialized in 2015, Micra devices are implanted directly inside the heart without leads or a surgical pocket and have treated more than 300,000 patients globally.

Twitter Facebook LinkedIn

Parent Company

Medtronic plc

Founded

2015

Status

Publicly Traded

Headquarters

Minneapolis, Minnesota, USA

Micra Timeline

1949

Medtronic plc

Parent company established in Galway, Ireland; operational headquarters Minneapolis, Minnesota, USA

Company Founded

2015

Micra

Founded by Medtronic (internal development)

Founded

GlobalOfficial Website

Who Owns Micra?

Parent Company: Medtronic plc
Ownership Type: Product line
Company Type: Publicly Traded
Stock Ticker: NYSE: MDT

Brand	Parent Company	Ownership Type
Micra	Medtronic plc	Product line

Where to Buy

Disclosure: We may earn commission from purchases

Micra on Amazon

History of Micra

Founded: 2015
Founders: Medtronic (internal development)

Conventional pacemakers had barely changed their architecture for fifty years when Medtronic began work on Micra: a pulse generator implanted in a chest pocket, connected to the heart by one or more wires called leads. Leads were the weak point. They could fracture, dislodge, or become infected, and they accounted for a disproportionate share of pacemaker complications.

Medtronic's answer was to eliminate the leads entirely by shrinking the whole device into a capsule small enough to sit inside the heart itself. The result, the Micra transcatheter pacing system, measured about 25.9 millimeters long and 0.8 cubic centimeters in volume, roughly the size of a large vitamin pill, and was delivered through a catheter in the femoral vein.

Micra earned CE Mark in 2015 and FDA approval in April 2016, making it the first leadless pacemaker approved in the United States. The original Micra VR paced the right ventricle alone. Medtronic added Micra AV in 2020, which used an accelerometer to sense atrial activity and coordinate ventricular pacing, restoring a degree of atrioventricular synchrony.

The second generation, Micra AV2 and Micra VR2, won FDA approval in 2023 with projected median battery life of 15.6 and 16.7 years respectively, improvements of roughly 40% over the first generation. Medtronic reports that more than 80% of patients are now projected to need only one Micra for life.

Adoption accumulated steadily: Micra passed 200,000 patients implanted worldwide in the early 2020s and exceeded 300,000 patients by 2025. More than 10,000 physicians are trained to implant the device, and the clinical record includes more than 350 published manuscripts and a post-approval registry showing a 4.5% major complication rate at five years.

About Medtronic plc

What does Medtronic own?
Medtronic owns the Medtronic device portfolio across cardiovascular, neuroscience, and surgical categories, including named product lines such as Micra, Hugo, Evolut, Mazor, StealthStation, and Valleylab. It no longer owns MiniMed, which became a fully independent public company in October 2026.

Is Medtronic publicly traded?
Yes. Medtronic plc trades on the New York Stock Exchange under ticker MDT and is a component of the S&P 500. It is an Irish-domiciled company that reports as a U.S. domestic issuer.

Who founded Medtronic?
Earl Bakken and his brother-in-law Palmer Hermundslie founded the company in a Minneapolis garage in 1949 as a medical equipment repair business. Bakken invented the first battery-powered wearable pacemaker in 1957.

Where is Medtronic headquartered?
Medtronic is legally domiciled in Galway, Ireland, following the 2015 Covidien acquisition. Its operational headquarters and executive leadership are in Minneapolis, Minnesota.

How many brands does Medtronic own?
Medtronic operates primarily as a master-brand company. Products carry Medtronic branding with trade names like Micra, Hugo, Evolut, and Symplicity. It has fewer than a dozen standalone consumer-facing names.

Who owns Medtronic?
The company is owned by public shareholders with no controlling interest. The largest holders are index investors including Vanguard, BlackRock, and State Street. Geoff Martha serves as Chairman and CEO.

Has Medtronic made major acquisitions recently?
The largest deal in company history was the $42.9 billion Covidien acquisition completed in 2015. More recently it acquired Mazor Robotics (2018, about $1.64 billion) and Affera (2022, about $1 billion). Its biggest recent transaction was a divestiture: the October 2026 separation of MiniMed.

What is Medtronic's revenue?
Medtronic reported FY2026 revenue of $36.4 billion, up 8.4%, its fastest annual growth in ten years. In Q1 FY2027 it posted $9.8 billion in revenue, up 13.7%, and raised full-year guidance.

Founded: 1949
Headquarters: Galway, Ireland; operational headquarters Minneapolis, Minnesota, USA
Company Type: Publicly Traded
Stock: NYSE: MDT
Revenue: $36.4 billion (FY2026, ended April 24, 2026)
Employees: Approximately 95,000

Visit Medtronic plc website

View full company profile for Medtronic plc

Where Is Micra Made / Based?

Headquarters: Minneapolis, Minnesota, USA
Manufacturing / Operations: United States, Puerto Rico

Micra Categories & Tags

Medical Devices Pacemakers Cardiology Medtech Healthcare

Micra Ownership: Pros & Cons

Advantages

+First and best-selling leadless pacemaker with more than 300,000 implants
+Published evidence shows roughly 53% fewer major complications than transvenous devices
+Second-generation battery life of 15.6 to 16.7 years supports one-device-for-life positioning
+Decade-long head start over the only rival, Abbott Aveir
+Backed by Medtronic's cardiac rhythm salesforce and clinical infrastructure

Considerations

-Limited to single and dual-chamber pacing; no resynchronization therapy option
-Cardiac perforation and tamponade risk, though low, persists in implant data
-Retrieval at end of life is difficult, a concern for younger patients
-Abbott Aveir's dual-chamber capability pressures the technology gap
-Premium pricing restricts adoption where reimbursement is limited

Frequently Asked Questions About Micra

Sources & Further Reading

Competitors to Micra

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
Boston Scientific	Boston Scientific	USA	1979	Mass market	Global	All Genders
MedtronicSister Brand	Medtronic	USA	1949	Mass market	Global	All Genders
Stryker	Stryker	USA	1941	Market leader	Global	All Genders
HugoSister Brand	Medtronic	USA	2021	Mass market	Global	All Genders
BD	Becton Dickinson	USA	1897	Mass market	Global	All Genders
GE Imaging	Ge Healthcare	USA	2023	Mass market	Global	All Genders